Literature DB >> 25586068

[Parkinson's disease and psychoses].

Jacopo Vittoriano Bizzarri1, Giancarlo Giupponi, Ignazio Maniscalco, Patrizia Schroffenegger, Andreas Conca, Hans Peter Kapfhammer.   

Abstract

Psychotic symptoms are common in Parkinson's disease (PD) and are associated with increased disability, worsened quality of life, and poor long-term prognosis. In this article, clinical features, hypotheses on pathogenesis, and current treatment strategies for Parkinson's disease psychosis (PDP) are reviewed. According to epidemiological studies, the prevalence of PDP is between 20 to 40 %. Complex visual hallucinations are the most common psychotic symptoms and are present in 17-72 % of the patients. Other sensory disturbances encompass tactile hallucinations and minor hallucinatory phenomena, such as sense of presence and visual illusions. Hallucinations are often accompanied by delusions, whose most frequent themes are persecution and jealousy. The pathophysiology of PDP remains unclear. Different factors have been implicated, including Levo-dopa and dopaminergic medications, neurotransmitter imbalances, neuroanatomic alterations, abnormal visuospatial processes, and genetic predisposition. The first-line strategy in the treatment of persistent and problematic PDP is represented by reduction in anti-PD medications. Second-generation antipsychotics are the treatment of choice, with clozapine being demonstrated as the most effective and tolerable drug for PD patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25586068     DOI: 10.1007/s40211-014-0132-8

Source DB:  PubMed          Journal:  Neuropsychiatr        ISSN: 0948-6259


  153 in total

1.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.

Authors:  Günes Kiziltan; Sibel Ozekmekçi; Sibel Ertan; Turan Ertan; Ethem Erginöz
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

2.  Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.

Authors:  P J Whitehouse
Journal:  Adv Neurol       Date:  1987

3.  Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

Authors:  D Aarsland; J P Larsen; K Karlsen; N G Lim; E Tandberg
Journal:  Int J Geriatr Psychiatry       Date:  1999-10       Impact factor: 3.485

4.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

Authors:  Claudio Pacchetti; Raffaele Manni; Roberta Zangaglia; Francesca Mancini; Enrico Marchioni; Cristina Tassorelli; Michele Terzaghi; Maria Ossola; Emilia Martignoni; Arrigo Moglia; Giuseppe Nappi
Journal:  Mov Disord       Date:  2005-11       Impact factor: 10.338

5.  Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

Authors:  Christopher G Goetz; Joanne Wuu; Linda M Curgian; Sue Leurgans
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

6.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

7.  Hallucinations in Parkinson's disease: a follow-up study.

Authors:  Anne Doé de Maindreville; Gilles Fénelon; Florence Mahieux
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

8.  Psychotic complications of long-term levodopa treatment of Parkinson's disease.

Authors:  A Friedman; J Sienkiewicz
Journal:  Acta Neurol Scand       Date:  1991-08       Impact factor: 3.209

9.  Aripiprazole and Parkinson's disease psychosis.

Authors:  Carlos Schönfeldt-Lecuona; Bernhard J Connemann
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

10.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

View more
  3 in total

Review 1.  Psychosis in Parkinson's disease: identification, prevention and treatment.

Authors:  Johannes Levin; Alkomiet Hasan; Günter U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2015-04-18       Impact factor: 3.575

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

3.  Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.

Authors:  Mei Yuan; Laura Sperry; Norika Malhado-Chang; Alexandra Duffy; Vicki Wheelock; Sarah Farias; Kevin O'Connor; John Olichney; Kiarash Shahlaie; Lin Zhang
Journal:  Brain Behav       Date:  2017-04-14       Impact factor: 2.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.